Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Vallon Pharmaceuticals, Inc. | vlon-20210331xex32d2.htm |
| EX-31.2 - EXHIBIT 31.2 - Vallon Pharmaceuticals, Inc. | vlon-20210331xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - Vallon Pharmaceuticals, Inc. | vlon-20210331xex31d1.htm |
| EX-10.2 - EXHIBIT 10.2 - Vallon Pharmaceuticals, Inc. | vlon-20210331xex10d2.htm |
| EX-10.1 - EXHIBIT 10.1 - Vallon Pharmaceuticals, Inc. | vlon-20210331xex10d1.htm |
| 10-Q - 10-Q - Vallon Pharmaceuticals, Inc. | vlon-20210331x10q.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 13, 2021 | By: | /s/ David Baker |
|
| David Baker |
|
| President and Chief Executive Officer |
|
| (Principal Executive Officer) |